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Systemic administration of a Connexin43 mimetic peptide, Peptide5, has been shown to 
reduce secondary tissue damage and improve functional recovery after spinal cord injury 
(SCI). This study investigated safety measures and potential off-target effects of Peptide5 
systemic administration. Rats were subjected to a mild contusion SCI using the New York 
University impactor. One cohort was injected intraperitoneally with a single dose of 
fluorescently-labelled Peptide5 and euthanised at 2 or 4 hours post-injury for peptide 
distribution analysis. A second cohort received intraperitoneal injections of Peptide5 or a 
scrambled peptide and were culled at 8 or 24 hours post-injury for analysis of connexin 
proteins and systemic cytokine profile. We found that Peptide5 did not cross the blood-spinal 
cord barrier in control animals, but reached the lesion area in the spinal cord-injured animals 
without entering non-injured tissue. There was no evidence that the systemic administration 
of Peptide5 modulates Connexin43 protein expression or hemichannel closure in the heart 
and lung tissue of SCI animals. The expression levels of other major connexin proteins 
including Connexin30 in astrocytes, Connexin36 in neurons and Connexin47 in 
oligodendrocytes were also unaltered by systemic delivery of Peptide5 in either the injured or 
non-injured spinal cords. In addition, systemic delivery of Peptide5 had no significant effect 
on the plasma levels of cytokines, chemokines or growth factors. These data indicate that the 
systemic delivery of Peptide5 is unlikely to cause any off-target or adverse effects and may 





Peptide5 is a synthetic peptide that mimics a sequence in the extracellular loop 2 of 
Connexin43, a ubiquitously expressed gap junction protein found in the spinal cord (Lee et al. 
2005; Stehberg et al. 2012; Theriault et al. 1997). Under pathological conditions, Connexin43 
channel-mediated communication is involved in secondary cell death by propagating 
neurotoxic molecules, such as glutamate, nitric oxide, lactate, arachidonate, ammonia, 
reactive oxygen species and calcium waves from injured cells to adjacent healthy cells, a 
process known as the bystander effect (Lin et al. 1998; Scemes et al. 2000; Theriault et al. 
1997). Additionally, the opening of uncoupled gap junction hemichannels alters the 
permeability of cell membranes to release neurotoxins to the extracellular space and can 
trigger calcium waves, which are then received by surrounding, previously uninjured cells 
(Davidson et al. 2015; Decrock et al. 2015; Orellana et al. 2011; Thompson et al. 2006; Ye et 
al. 2003). Peptide5 is able to regulate the communication of Connexin43 gap junctions and 
hemichannels independently, with short incubation times or low concentration restricting 
hemichannel opening without affecting the communication of existing gap junctions, whereas 
long incubation times or high concentration have been reported to prevent gap junction and 
hemichannel communication in experimental preclinical models (Abudara et al. 2014; 
Leybaert et al. 2003; O'Carroll et al. 2008; Yoon et al. 2010). Although the exact mechanisms 
of Peptide5 action remain to be fully elucidated, the most recent study revealed that Peptide5 
acts on the extracellular loop 2 of Connexin43 (Kim et al. 2017). The authors also 
demonstrated that the Peptide5 sequence provides the most effective Connexin43 
hemichannel blocking, with the SRPTEKT motif being central to the Peptide5 mechanism 
(Kim et al. 2017). 
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Using an intrathecal catheter and an osmotic pump to deliver Peptide5 directly to the lesion 
area of the spinal cord in a rat contusion model, early studies demonstrated the 
neuroprotective efficacy of Peptide5 (O’Carroll et al. 2013). Local application of Peptide5 
has also been explored in a number of pathological conditions in the nervous system 
including retinal ischaemia (Chen et al. 2015; Chen et al. 2014), cerebral ischaemia 
(Davidson et al. 2015; Davidson et al. 2013a; Davidson et al. 2013b), foetal ischaemia 
(Davidson et al. 2012a) and asphyxia (Davidson et al. 2014). Local administration may not be 
the most practical option for human spinal patients as, for example, the intrathecal delivery of 
Peptide5 may normally involve an invasive procedure immediately after a traumatic event, 
that may not be clinically prudent. Systemic administration is able to deliver proteins and 
mimetic peptides to the lesion area of the spinal cord even where the capillary bed has been 
compromised (Han et al. 2010), thus offering a practical therapeutic approach for people with 
spinal cord injury (SCI). A study of retinal ischemia-reperfusion with systemic Peptide5 
delivery showed significant neuronal protection following peptide treatment (Danesh-Meyer 
et al., 2012) and a recent study by us has shown that systemic Peptide5 delivery is 
neuroprotective and improves functional recovery in a rat spinal cord contusion model (Mao 
et al. 2017). However, the safety profile of Peptide5 after systemic administration has not 
been experimentally examined. 
 
Connexin43 protein is found in other tissues, including the heart (Gourdie et al. 1993; Gu et 
al. 2014; Van Kempen et al. 1991), brain (Deng et al. 2014; Nakase et al. 2004; Yamamoto et 
al. 1990), testis (Chevallier et al. 2013; Li et al. 2010; Steger et al. 1999), skin (Chang et al. 
2015; Guo et al. 1992; Tada and Hashimoto 1997) and bone marrow (Dorshkind et al. 1993; 
Dürig et al. 2000; Zhang et al. 2006). Connexin43 mimetic peptides have been shown to 
regulate Connexin43 hemichannels and protect against ischaemic injury in the heart (Hawat 
 5 
et al. 2010; Hawat et al. 2012) and brain (Davidson et al. 2015; Davidson et al. 2013a; 
Davidson et al. 2013b). Following our demonstration that systemic delivery of Peptide5 is 
protective after SCI (Mao et al. 2017), we sought to assess whether Connexin43 
hemichannels and/or gap junctions in tissues such as the heart are affected by this treatment. 
 
In the spinal cord, there is a wide distribution of connexin gap junctions: astrocyte/astrocyte 
gap junctions contain Connexin30 and 43, neuron/neuron gap junctions contain Connexin36, 
and oligodendrocyte/astrocyte gap junctions containing Connexin29, 32 and 47, with the 
major heterotypic gap junction channels being composed of Connexin43-Connexin47 and 
Connexin30-Connexin32 protein combinations (Kleopa et al. 2004; Lee et al. 2005; 
Orthmann-Murphy et al. 2008; Rash et al. 2001; Rash et al. 1998; Tonkin et al. 2015). 
Although Connexin43 is the major connexin that has been reported to be altered following 
traumatic SCI, we also sought to evaluate whether that the expression of other connexins may 
be changed following blockade of Connexin43 hemichannels by Peptide5 treatment. 
 
In the current study, therefore, as an initial step towards translation to human SCI treatments, 
we examined safety aspects of Peptide5 systemic administration protocols including tissue 
distribution and systemic effects in our rat spinal cord injury model. 
Materials and Methods 
Animals and animal care 
All experimental protocols and procedures used in the current study were approved by the 
Animal Care and Ethics Committee of University of Technology Sydney, in accordance with 
the guidelines of the National Health and Medical Research Council of Australia. There were 
57 adult female Sprague-Dawley rats weighing 250-300 g used (Animal Resource Centre, 
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Perth, Australia). All animals were maintained in standard cages with ad-lib water and food 
on a 12:12 hour light-dark cycle. Each animal’s weight was checked at least twice a week.  
The surgical procedures have been described previously in detail (Mao et al. 2017). Briefly, 
rats were anesthetised with 4% isoflurane in 1 L/min oxygen and maintained at 2% isoflurane 
in 1 L/min oxygen. Local anaesthetic (bupivacaine, 0.5%, 0.02 mL) was injected at the 
surgical sites before an incision was made through skin and muscle layers over the dorsal 
midline. A T10 laminectomy was performed to expose the spinal cord and, in the  
‘SCI’ groups (n = 30), animals were subject to a mild contusion injury (6.25 mm drop, 10 g 
weight) to the T10 spinal cord by using the New York University impactor. The ‘sham’ 
group (n = 19) were subject to a T10 laminectomy only without SCI. The ‘intact controls’ (n 
= 8) did not receive any surgical procedures. A summary of the animal cohorts and tissue 
samples obtained is provided in Table 1. 
 
Peptide treatment 
Peptide5 was designed to mimic a portion of the extracellular loop 2 of Connexin43 as 
described previously (O'Carroll et al. 2008). All peptides were solid phase synthesised, using 
chemistries on a Protein technologies, Symphony instrument, purified by high-performance 
liquid chromatography and the structure confirmed by mass spectrometry analysis. The dose 
of peptides used was chosen to match previous studies (Danesh-Meyer et al. 2012; Mao et al. 
2017), in order to give an initial blood concentration of 100 µM. In the first cohort, a single 
dose of fluorescein isothiocyanate (FITC)-conjugated Peptide5 (sequence FITC-A-
VDCFLSRPTEKT, Auspep; 3.5 mg in 0.5 ml saline, equivalent to 10 mg/kg of Peptide5) 
was injected intraperitoneally to the SCI (n = 8) and intact control (n = 8) rats immediately 
after surgery. In the second cohort, three doses of Peptide5 (sequence VDCFLSRPTEKT, 
Mimotopes) or scrambled peptide (SP) (sequence RFKPSLCTTDEV, Mimotopes) were 
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delivered intraperitoneally to SCI (n = 22) and sham (n = 16) rats at 0 hours (10 mg/kg in 0.5 
ml saline), 2 hours (5 mg/kg in 0.5 ml saline), and 4 hours (2.5 mg/kg in 0.5 ml saline) 
following surgery. A single dose of vehicle control (0.5 ml saline) was delivered 
intraperitoneally to sham animals (n = 3).  
Post-operative care  
Post-operative animals were housed individually and given subcutaneous antibiotics 
(cephalothin sodium, 0.33 mg/kg), analgesics (buprenorphine hydrochloride, 0.03 mg/kg), 
and supplementary fluid (Hartman replacement solution, 3.8 ml) twice daily. Bladders were 
expressed manually twice daily. 
Euthanasia and tissue preparation 
The FITC-Peptide5 treated animals were euthanized with sodium pentobarbital (100 mg/kg, 
i.p.) and perfused intracardially with 200 ml of heparinized saline at 2 hours (n = 8) and 4 
hours (n = 8) after surgery. Approximately 10 mm of spinal cord centred at T10 and cervical 
enlargement as well as the major organs (brain, heart, lung, liver, spleen and kidney) were 
dissected for generating fresh frozen sections of 15 µm onto Matsunami Platinum PLC-14 
glass slides, using a cryostat (Leica, CM1950). Slides were rehydrated in water for 5 minutes 
and cover-slipped in fluorescent mounting medium (Dako). 
The Peptide5 or SP treated animals were euthanized at 8 hours (n = 6) and 24 hours (n = 35) 
post-injury with sodium pentobarbital (100 mg/kg, i.p.). Cardiopuncture was then performed 
to collect 5 ml of blood, and the plasma was extracted. Intracardial perfusion using 
heparinized saline and 4% paraformaldehyde was performed. Approximately 20 mm of 
spinal cord centred at T10 were dissected and post-fixed in 4% paraformaldehyde overnight 
and then stored in 30% sucrose, while hearts and lungs were removed and post-fixed in 10% 
formalin. Spinal cords were sectioned horizontally in a cryostat (Leica, CM1950). Sections 
were mounted in a series of 10 so that each section on a slide was at 150 µm intervals. 
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Approximately 5 x 5 x 3 mm3 of heart and lung specimens along with a representative lumbar 
spinal cord specimen (SCI with Peptide5 treatment at 8 hours post-injury) were processed for 
paraffin embedding and sections were cut at 5 µm. Mayer’s haematoxylin and eosin (H&E) 
staining was performed to assess tissue morphology. 
Immunohistochemistry 
Slides were rehydrated in xylene, decreasingly graded ethanol and phosphate buffered saline 
with Triton X-100 at pH 7.4 (PBST), and incubated in 5% normal goat serum (NGS) in 
PBST for 30 minutes. Primary antibodies were diluted in phosphate buffer with 2% NGS 
(PBG) and incubated overnight at 4 °C. For the frozen sections of T10 spinal cord, primary 
antibodies used were rabbit anti-Connexin30 (1:250, Thermo Fisher), rabbit anti-Connexin36 
(1:250, Thermo Fisher) and rabbit anti-Connexin47 (1:250, Thermo Fisher). For the paraffin 
sections of heart and lung, primary antibodies used were rabbit anti-Connexin43 (1:2000, 
Sigma-Aldrich) and rabbit-phosphorylated Connexin43-Ser368 (1:100, Santa Cruz). The 
phosphorylation of Connexin43 at Ser368 was used to recognise the closed state of 
Connexin43 hemichannels (Faigle et al. 2008; Lampe et al. 2000; O’Carroll et al. 2013). 
Slides were then washed in PBST and incubated with secondary antibodies: goat anti rabbit 
Alexa Fluor 488 (Connexin30, 36, 43 and 47; 1:200, Thermo Fisher) or goat anti-rabbit 
Alexa Fluor 568 (phosphorylated Connexin43; 1:200, Thermo Fisher) in PBG for 2 hours at 
room temperature. Primary antibodies were omitted from negative controls. All slides were 
cover-slipped in fluorescent mounting medium (Dako). 
 
Representative paraffin sections of lumbar spinal cord were used to demonstrate the co-
localisation of Connexin30 on astrocytes, Connexin36 on neurons, Connexin43 on astrocytes, 
and Connexin47 on oligodendrocytes. Slides were rehydrated in xylene, decreasingly graded 
ethanol and PBST. Heat-induced antigen retrieval was performed in citrate buffer (10 mM 
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citric acid, pH 6.0) for 10 minutes in a pressure cooker for Connexin36/neuronal nuclei 
(NeuN) staining.  All sections were incubated in blocking agents for 30 minutes at room 
temperature (5% NGS in PBST for Connexin30/glial fibrillary acidic protein (GFAP), 
Connexin43/GFAP and Connexin47/oligodendrocyte specific protein (OSP); 5% skim milk 
for Connexin36/NeuN). The primary antibodies of rabbit anti-Connexin30 (1:250, Thermo 
Fisher), rabbit anti-Connexin36 (1:250, Thermo Fisher), rabbit anti-Connexin43 (1:2000, 
Sigma-Aldrich) or rabbit anti-Connexin47 (1:250, Thermo Fisher) were diluted in PBG and 
incubated overnight at 4 ºC. After washing in PBST three times, the slides were incubated 
with secondary goat anti-rabbit Alexa Fluor 488 or 568 antibody (1:200, Thermo Fisher) in 
PBG for 2 hours at room temperature. After washing in PBST five times, the slides were 
incubated with primary antibodies of rabbit anti-GFAP (1:1000, Dako), mouse anti-NeuN 
(1:1000, Millipore) or rabbit anti-OSP (1:3000, Abcam) in PBG overnight at 4 ºC. Following 
washing in PBST three times, the slides were incubated with the secondary goat anti-rabbit 
Alexa Fluor 488 or 568 antibody (1:200, Thermo Fisher) in PBG for 2 hours at room 
temperature. Slides were then washed with PBST and counterstained by Hoechst (1:5000, 
Thermo Fisher) for 10 minutes. Primary antibodies were omitted from negative controls. All 
slides were cover-slipped in fluorescent mounting medium (Dako). 
Imaging and quantification 
Imaging was conducted using an Olympus BX-51 light microscope with an Olympus U-RFL-
T fluorescence burner and appropriate filters. The black balance was adjusted using the 
negative control sections to normalise the mean grey scale value (GSV). Frozen spinal cord 
sections were aligned using the central canal as an anatomical landmark (midline) for 
immunohistochemistry analysis. Images were taken adjacent to the lesion and at both 3.5 and 
7 mm distal to the lesion centre in both rostral and caudal directions. Image analysis was 
conducted using ImageJ software (National Institutes of Health, version 2X). Analysis of 
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fluorescent immunohistochemistry was undertaken by measuring the total fluorescent 
intensity per image, mean GSV, in 20x images. High power images (100x) were taken for the 
double labelling of connexins and neural markers for visualising the distribution. 
Multiplex assay 
The plasma samples obtained from the 24-hour post-injury groups in Cohort II (n = 8 per 
group) were used for a multiplex assay to compare cytokines, chemokines and growth factors, 
as per manufacturer protocol (Bio-Rad, Bio-Plex Pro™ Rat Cytokine 23-Plex Assay 
#L8001V11S5). Briefly, plasma samples were diluted 1:4 and analysed following the 
manufacturer’s instructions. The plates were pre-wetted with wash buffer (Bio-Rad) and 
loaded with 1 × beads (Bio-Rad). The wells were rinsed by wash buffer (Bio-Rad) and then 
loaded with blank, standards, or samples for one-hour incubation. Following washing thre 
times, the detection antibodies were added for 30-minute incubation. The plates were washed 
and incubated in streptavidin-phycoerythrin for 10 minutes. After washing, the analytes were 
resuspended with assay buffer (Bio-Rad) for 30 seconds. The plates were read using the Bio-
Plex reader (Bio-Rad), and results were converted to a pg/ml concentration for all of the 
cytokines tested. 
Statistical analysis 
All data were expressed as mean ± standard error of the mean (SEM). Unpaired t-test or one-
way analysis of variance (ANOVA) with a Bonferroni post-hoc test was used to determine 
significant differences (PRISM, Version 6.0e, GraphPad). Differences were considered 
statistically significant at p < 0.05. There were no significant differences between rostral and 
caudal measurements in mean GSV using the paired t-test and, therefore, the mean of rostral 




Distribution of Peptide5 in vivo 
All surgical procedures and intraperitoneal injections of FITC-Peptide5 were conducted 
without incident. None of the rats showed any indication of complications from the SCI 
surgery or intraperitoneal injection. FITC-Peptide5 was visualised as green fluorescence in 
the frozen sections (Figure 1). There was no evidence of FITC-Peptide5 distribution in the 
cervical enlargement of spinal cord, brain, heart and liver tissue in either intact or SCI 
animals. FITC-Peptide5 was found in lung, spleen and kidney tissue in both control and SCI 
animals. FITC-Peptide5 presented in the T10 segment of spinal cord in the SCI rats, but not 
the intact controls.  
 
Connexin43 protein in the heart tissue 
Due to the known abundance of Connexin43 protein in the heart, additional investigation was 
undertaken using histology to confirm that there was no obvious alteration to the cardiac 
tissue or connexin43 levels as a result of peptide treatment. Heart sections stained by Mayer’s 
H&E showed the typical histological characteristics of cardiac muscle: single central nuclei, 
branching cell shape and muscle striation (Figure 2A). There were no observed differences in 
the histological morphology of heart tissue or the distribution of fluorescent staining between 
groups. Fluorescent immunohistochemistry staining demonstrated Connexin43 (Figure 2B) 
and phosphorylated Connexin43 at residue Ser368 (Figure 2C) proteins in the intercalated 
discs of heart tissue. The immunoreactivity levels of Connexin43 and phosphorylated 
Connexin43 were measured by mean GSV for statistical analysis. There were no statistically 
significant differences in the immunohistochemistry labelling intensity of Connexin43 (36.06 
± 9.32) between groups (Figure 2D). Similarly, no significant differences were found in the 
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immunohistochemistry staining intensity of Connexin43 phosphorylation at residue Ser368 
(18.86 ± 3.73) between groups using one-way ANOVA analysis (Figure 2E). 
 
Connexin43 protein in the lung tissue 
Due to the observation of FITC-Peptide5 in the lung sections additional investigation was 
undertaken using histology to confirm that there was no obvious alteration to the respiratory 
tissue or connexin43 levels as a result of peptide treatment. Lung sections stained by Mayer’s 
H&E staining showed histological characteristics typical of alveolar tissue: alveolar wall 
lined by type 1 pneumocytes (squamous epithelial cells) and type 2 pneumocytes (cuboidal 
epithelial cells), as well as alveolar macrophages found in the alveolar ducts and sacs (Figure 
3A). In particular, the thickness of the alveolar wall and the number of erythrocytes were 
significantly increased in both spinal cord injured and sham rats compared with that expected 
in intact rats (Abdelaziz et al. 2016; Gauter-Fleckenstein et al. 2014; van den Brule et al. 
2014). The alveolar wall was partially incomplete in all lung samples. However, there were 
no observed differences in the histological morphology of lung tissue between groups. 
Fluorescent immunohistochemistry indicated that there was no Connexin43 protein located in 
lung tissue, so no further fluorescent immunohistochemistry staining of Connexin43 
phosphorylation at residue Ser368 was conducted. The FITC-Peptide5 observed in the lungs 
is thought to be due to an artefact of cardiac perfusion.  
 
Major connexin proteins in the spinal cord tissue 
Immunohistochemical co-labelling for Connexin43 and GFAP, Connexin30 and GFAP, 
Connexin36 and NeuN, as well as Connexin47 and OSP was performed to determine the 
location of Connexin43, 30, 36 and 47 in the rat spinal cord (Figure 4). Connexin30 and 43 
expression was found to be associated with astrocytes and their processes labelled for GFAP. 
Neuronal cells labelled by NeuN co-expressed Connexin36 protein in the spinal cord. 
Connexin47 expression was found to be associated with oligodendrocytes and their processes 
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labelled by OSP. We previously demonstrated that SCI causes an upregulation of 
Connexin43, which is decreased by treatment with Peptide5 (Mao et al., 2017). We therefore 
further analysed expression levels of Connexin30, 36 and 47 in the T10 frozen spinal cord 
sections at 8 and 24 hours following injury.  
 
Protein levels of Connexin30, 36 and 47 were measured by mean GSV of 
immunohistochemistry labelling intensity in both grey and white matter at 3.5 and 7 mm 
distal to the lesion centre and the epicentre of the lesion. At all anatomical locations, there 
were no statistically significant differences in Connexin30 protein levels between groups in 
both grey (7 mm: 31.28 ± 3.14, 3.5 mm: 30.67 ± 3.08, Epicentre: 35.38 ± 4.27) and white 
matter (7 mm: 17.19 ± 2.00, 3.5 mm: 17.50 ± 2.43, Epicentre: 17.35 ± 2.69) (Figure 5). The 
expression levels of Connexin36 were also not significantly different between groups in 
either grey (7 mm: 21.26 ± 1.91, 3.5 mm: 21.11 ± 1.99, Epicentre: 21.55 ± 1.88) or white 
matter (7 mm: 10.82 ± 1.35, 3.5 mm: 11.11 ± 1.45, Epicentre: 11.78 ± 1.11) (Figure 6). 
Similarly, there were no statistically significant differences found in Connexin47 protein 
levels between groups in both grey (7 mm: 35.56 ± 1.40, 3.5 mm: 35.64 ± 1.70, Epicentre: 
35.37 ± 2.13) and white matter (7 mm: 23.52 ± 1.39, 3.5 mm: 23.22 ± 1.26, Epicentre: 22.31 
± 2.72) (Figure 7). 
 
Cytokine profile in the plasma 
To evaluate whether systemic delivery of Peptide5 may affect peripheral immune responses, 
we tested the cytokine profile in plasma samples removed from the rats at 24 hours after 
injury. Using a multiplex assay for rat plasma samples, nine of the analytes tested showed 
reportable plasma values. These were IL (interleukin)-5, IL-18, chemokine (C-C motif) 
ligand 5 (RANTES), chemokine (C-X-C motif) ligand 1 (GROKC), monocyte 
chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 3α (MIP-3A), 
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erythropoietin (EPO), macrophage colony-stimulating factor (M-CSF) and vascular 
endothelial growth factor (VEGF). Table 2 summarises the mean concentration for each of 
the analytes in pg/ml. No significant differences were detected between groups for any of the 
plasma cytokine analytes using a one-way ANOVA. 
Discussion 
The data presented here shows that the systemic administration of Peptide5 to rats did not 
appear to cause any off-target or adverse effects in either control or SCI animals. As 
anticipated, Peptide5 was delivered to the lesion area of the spinal cord. This is because the 
permeability of the blood spinal cord-barrier (BSCB) is significantly increased following 
traumatic SCI (Bilgen et al. 2002; Gordh et al. 2006; Popovich et al. 1996) and the capillary 
bed at the lesion area is compromised (Figley et al. 2014; Soubeyrand et al. 2014). This 
provides an opportunity for Peptide5 to leak from the disrupted blood vessels of the vascular 
system into the damaged spinal cord tissue. Under normal physiological conditions, the 
selective permeability of the blood brain and/or spinal cord barrier prevents small molecules 
(< 10 kDa) from entering the central nervous system (CNS) tissue (Habgood et al. 2007; 
Popovich et al. 1996). As shown in the current study, the FITC-labelled Peptide5 (< 2 kDa) 
was not detected in the non-injured tissue of the CNS. 
 
Peptide5 in the spinal cord tissue 
Peptide5 is synthesised to mimic a sequence on the extracellular loop 2 of Connexin43 (Kim 
et al. 2017). Systemic administration of Peptide5 has been shown to successfully regulate 
Connexin43 protein expression levels and hemichannel closure in the injured spinal cord 
(Mao et al. 2017), and we now show here that the protein (gap junction labelling) levels of 
Connexin 30, 36 and 47 were unaltered using immunohistochemistry. Connexin30, 
abundantly expressed on astrocytes, is found in astrocyte/astrocyte gap junctions (Nagy et al. 
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1999; Rash et al. 2001) and has not been reported change in the spinal cord following 
traumatic injury. In the current study, there was no evidence that the Connexin30 expression 
levels and patterns altered in response to SCI or Peptide5 treatment. Even though the 
expression of Connexin30 and 43 is tightly regulated by neurons (Koulakoff et al. 2008), 
further studies should  investigate the interaction and relationship between these two main 
astrocytic connexins. Connexin36 is the major connexin found in neuron/neuron gap 
junctions (Lee et al. 2005; Rash et al. 2000; Rash et al. 2001). In agreement with a previous 
study (Lee et al. 2005), the current study demonstrated that Connexin36 expression 
surrounding the lesion in the spinal cord did not alter in response to traumatic injury, nor was 
it affected by Peptide5 treatment. However, Yates et al. (2008) observed a downregulation of 
Connexin36 protein at the lumber enlargement distal to the injury area at 7 days after a 
complete T10 transection in rats. The change in Connexin36 protein below the lesion level, in 
association with decreased electrical coupling, has been suggested to contribute to 
hyperreflexia and spasticity after SCI (Yates et al. 2008; Yates et al. 2011). However, the 
effect of Peptide5 distal to the lesion was not examined specifically in the current study. 
Connexin47, localised to oligodendrocytes, is known to dock with Connexin43 on astrocytes 
in astrocyte/oligodendrocyte gap junctions (Kamasawa et al. 2005; Kleopa et al. 2004; Li et 
al. 2004). Connexin47 expression has not been reported to change following a traumatic 
event on the spinal cord, despite increased expression of Connexin43 on astrocytes. This may 
suggest that the upregulated Connexin43 following SCI contributes primarily to the gap 
junctions between astrocytes rather than between astrocytes and oligodendrocytes.  
 
Peptide5 in other tissues 
There was no evidence of Peptide5 entering the heart tissue, indicating that Peptide5 remains 
in the vascular system rather than affecting the Connexin43 hemichannels on cardiomyocytes. 
This was further confirmed by the immunohistochemistry studies, showing that both 
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Connexin43 protein and phosphorylated Connexin43 protein (hemichannel closure) levels in 
the heart tissue did not differ between Peptide5 treatment and controls at either 8 or 24 hours 
following SCI.  
Peptide5 has been used for other applications, such as retinal ischaemia (Chen et al. 2015; 
Chen et al. 2014; Danesh-Meyer et al. 2012), cerebral ischaemia (Davidson et al. 2012b) and 
in an epileptiform lesion model (Yoon et al. 2010), but potential off-target effects on 
cardiomyocytes has not been reported. Another Connexin43 mimetic peptide, Gap26 
(sequence VCYDKSFPISHVR), synthesised to modulate Connexin43 hemichannels on 
cardiomyocytes. has been reported to protect the intact heart against ischaemia reperfusion 
injury ex vivo (Hawat et al. 2010) and the ischemic heart against myocardial infarction in vivo 
(Hawat et al. 2012). Given these results, it is not likely that systemically delivered Peptide5 
will cause any adverse impact on intact heart tissue. 
Peptide5, via systemic delivery, is not expected to affect lung tissue in vivo since Connexin43 
expression has not been reported in pneumocytes (Chang et al. 2013; Ishikawa et al. 2012; 
Márquez-Rosado et al. 2012; Rottlaender et al. 2010), but it maybe present in the blood 
vessels throughout the respiratory system (Rummery et al. 2002). In the current study, 
Connexin43 was not detected in lung sections by fluorescent immunohistochemistry staining 
in any group, but there was FITC-P5 present in the tissue sections of SCI and Sham animals, 
as well as abnormal histological morphology shown by H&E staining in all groups.  
FITC-labelled Peptide5 found in the spleen and kidney tissue was not unexpected. The spleen, 
a critically important immune organ combining both innate and adaptive immunities, is 
responsible for capturing and destroying pathogens and foreign bodies (Cesta 2006; Mebius 
and Kraal 2005). Peptide5, as a foreign body appears to be detected by the antigen-presenting 
cells in the spleen, such as dendritic cells, and may be being cleared by phagocytosis 
(Eloranta and Alm 1999; LopesCarvalho and Kearney 2004; van Rooijen 1990). However, 
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Peptide5 could also be filtered through the glomeruli into urine, as the high permeability of 
the glomerular capillary wall allows the molecules smaller than albumin to pass into the 
filtrate (Lund et al. 2003; Sandoval et al. 2012; Venkatachalam and Rennke 1978). Similarly, 
a few recent studies of tissue distribution observed the accumulation of other pharmaceutical 
and biological agents in the spleen and their excretion through urine (Aubert et al. 2012; 
Baek et al. 2012; Cho et al. 2013; Jasim et al. 2015; Liang et al. 2013).  
 
Systemic effects of Peptide5  
While it is expected that there would be inflammatory changes, such as increase in pro-
inflammatory cytokines, at the site of injury in the spinal cord tissue, the effects of SCI on 
circulating cytokines is less clear. We therefore investigated SCI and Peptide5 treatments 
alters systemic cytokine profile. Our results demonstrate that there was no systemic 
inflammatory response as a result of either the SCI or the Peptide5 treatment. This further 
supports that there are no off-target effects of Peptide5 that might result in wide spread 
inflammatory changes. We have, however, previously shown that IL-1β and TNFα are 
significantly up regulated in spinal cord itself after injury (O’Carroll et al. 2013). This does 
not appear to translate to significant changes in plasma cytokines, however, at least at the 24 
hours post-injury time point. Prior to clinical translation further toxicity studies will be 
required to determine if peptide5 causes any subtler immunomodulatory changes. Neither 
sham animals treated with Peptide5 nor animals treated with the SP control showed any 
evidence of adverse effects in this study or in other studies using Peptide5 (Danesh-Meyer et 
al. 2012; Davidson et al. 2012a). Further, there were no statistically significant differences 
between Peptide5 and SP-treated sham animals in previously undertaken molecular, cellular 
and behavioural analyses (Mao et al. 2017). It is suggested that Peptide5 rarely travels to the 
uninjured tissue, nor should it act globally on gap junctions in other organs at the low 
concentration used in the current study. While, higher doses may prove adverse, as reported 
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for example in a foetal model of ischaemia in sheep (Davidson et al. 2013b), systemic effects 
of low dose Peptide5 have not been reported in any in vivo models when delivered locally 
(Chen et al. 2015; Chen et al. 2014; Danesh-Meyer et al. 2012; Davidson et al. 2015; 
Davidson et al. 2013a; Davidson et al. 2013b; Davidson et al. 2014; O’Carroll et al. 2013), or 
systemically (Danesh-Meyer et al., 2012; Mao et al., 2017). Similarly, Hawat et al. (2012) did 
not report any systemic or adverse events after intravenous injection of another Connexin43 
mimetic peptide, Gap26, into rats with myocardial infarction.  
 
Given the short timeframe of 24 hours in the current study, further investigation is required to 
determine whether there are any the long-term effects of systemic Peptide5 treatment on the 
injured spinal cord and other uninjured tissues, and it will be necessary to establish a full 
toxicity profile for systemic Peptide5 delivery prior to human testing. Our results, however, 
suggest that the systemic administration of Peptide5 is unlikely to result in deleterious effects 
on the non-injured spinal cord, other major organs and systemic inflammatory responses, and 
this peptide is expected offer a safe treatment option for traumatic SCI. 
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Table 1 Summary of animal cohorts and tissue samples obtained. 










Fresh spinal cord at T10 and 
cervical, brain, heart, lung, 
liver, spleen and kidney  
Histology 
(n = 4 per group) 
II 
SCI Three doses of P5 or SP 8 Hours 
PFA fixed spinal cord at T10, 
heart and lung  
H&E and IHC 





of P5 or SP 24 hours 
PFA fixed spinal cord at T10, 
heart and lung 
 
Fresh plasma 
H&E and IHC 
(n = 3 per group) 
 
Multiplexes assays 
(n = 8 per group) 
Sham One dose of Saline 24 hours PFA fixed heart and lung 
H&E and IHC 
(n = 3 per group) 




Table 2 Comparison of cytokines, chemokines and growth factors in rat plasma 
24 hours after injury. There were no significant differences between groups for 
any of the analytes using a one-way analysis of variance. 

















































































EPO: Erythropoietin; GROKC: Chemokine (C-X-C motif) ligand 1; IL: Interleukin; 
MCP-1: Monocyte chemoattractant protein 1; MIP-3A: Macrophage inflammatory protein 3α; 
M-CSF: Macrophage colony-stimulating factor; P5: Peptide5; SCI: Spinal cord injury;  
SP: Scrambled peptide; RANTES: Chemokine (C-C motif) ligand 5; 
VEGF: Vascular endothelial growth factor 
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Figure 1 Distribution of fluorescein isothiocyanate labelled Peptide5 in intact and spinal 
cord injury rats.  
The fluorescein isothiocyanate (FITC) labelled Peptide5 was shown in green fluorescence. 
FITC-Peptide5 presented in the lung, spleen and kidney tissue in both normal and SCI 
animals, as well as the T10 spinal cord in the SCI rats. 
 
Figure 2 Histological morphology and immunohistochemistry staining of Connexin43 
and phosphorylated Connexin43 in the heart tissue.  
(A) Mayer’s Haematoxylin and Eosin staining showed no differences in the histological 
morphology of cardiac muscle between groups. Scale bar = 150 µm. (B) Representative 
images of fluorescent immunohistochemistry staining showed the Connexin43 (green) in the 
heart tissue. Scale bar = 150 µm. (C) Representative images of fluorescent 
immunohistochemistry staining showed the Connexin43 phosphorylation at residue Ser368 
(red) in the heart tissue. Scale bar = 150 µm. (D) Immunohistochemistry analysis showed no 
statistically significant differences in the level of Connexin43 immunoreactivity in the heart 
tissue between groups. (E) Immunohistochemistry analysis showed no statistically significant 
differences in the level of phosphorylated Connexin43 immunoreactivity in the heart tissue 
between groups. (GSV: greyscale value; P5: Peptide5; p-Connexin43: phosphorylated 
Connexin43; SCI: spinal cord injury; SP: control scrambled peptide) 
 
Figure 3 Histological morphology and immunohistochemistry staining of Connexin43 in 
the lung tissue.  
Mayer’s Haematoxylin and Eosin staining showed no differences in histological morphology 
of alveolar tissue between groups. Scale bar = 150 µm. (P5: Peptide5; SCI: spinal cord injury; 
SP: control scrambled peptide) 
 
Figure 4 Immunohistochemistry co-labelling of major connexin proteins and neural 
markers at 8 hours following spinal cord injury.   
(A) Connexin43 protein (red) was associated with astrocytes (yellow arrow) labelled by glial 
fibrillary acidic protein (GFAP) (green). (B) Connexin30 protein (red) was associated with 
astrocytes (white arrow) labelled by GFAP (green). (C) Neurons (yellow arrow heads) 
labelled by neuronal nuclear antigen (NeuN) (red) was co-labelled with Connexin36 protein 
(green). (D) Connexin47 protein (red) was associated with oligodendrocytes (white arrow 
heads) labelled by oligodendrocyte specific protein (OSP) (green). All nuclei were 
counterstained by Hoechst in blue.  
 
Figure 5 Immunohistochemistry staining of Connexin30 in rat spinal cord at 8 and 24 
hours following injury.  
(A) Representative images of Connexin30 immunofluorescence (green) at the epicentre of the 
lesion. Scale bar = 40 µm. (B) Immunohistochemistry analysis showed the Connexin30 
protein levels in both grey and white matter at 3.5 and 7 mm distal to the lesion centre and 
the epicentre of the lesion without any significant differences between groups. (GSV: 
greyscale value; P5: Peptide5; SCI: spinal cord injury; SP: control scrambled peptide) 
 
Figure 6 Immunohistochemistry staining of Connexin36 in rat spinal cord at 8 and 24 
hours following injury.   
(A) Representative images of Connexin36 immunofluorescence (green) at the epicentre of the 
lesion. Scale bar = 40 µm. (B) Immunohistochemistry analysis showed the Connexin36 
protein levels in both grey and white matter at 3.5 and 7 mm distal to the lesion centre and 
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the epicentre of the lesion without any significant differences between groups. (GSV: 
greyscale value; P5: Peptide5; SCI: spinal cord injury; SP: control scrambled peptide) 
 
Figure 7 Immunohistochemistry staining of Connexin47 in rat spinal cord at 8 and 24 
hours following injury.   
(A) Representative images of Connexin47 immunofluorescence (green) at the epicentre of the 
lesion. Scale bar = 40 µm. (B) Immunohistochemistry analysis showed the Connexin47 
protein levels in both grey and white matter at 3.5 and 7 mm distal to the lesion centre and 
the epicentre of the lesion without any significant differences between groups. (GSV: 
greyscale value; P5: Peptide5; SCI: spinal cord injury; SP: control scrambled peptide) 
 
 
 







